Alvotech (ALVO) Competitors

Genmab A/S (NASDAQ:GMAB) and Alvotech (NASDAQ:ALVO) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, institutional ownership, valuation, community ranking, profitability, earnings, risk, analyst recommendations and media sentiment.

Which has better earnings & valuation, GMAB or ALVO?

Genmab A/S has higher revenue and earnings than Alvotech. Alvotech is trading at a lower price-to-earnings ratio than Genmab A/S, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Genmab A/S	$2.39B	6.00	$631.91M	$1.03	21.06
Alvotech	$93.38M	42.91	-$551.73M	-$1.85	-7.18

Does the MarketBeat Community prefer GMAB or ALVO?

Genmab A/S received 155 more outperform votes than Alvotech when rated by MarketBeat users. Likewise, 62.65% of users gave Genmab A/S an outperform vote while only 46.15% of users gave Alvotech an outperform vote.

Company	Underperform	Outperform
Genmab A/S	Outperform Votes 161 62.65%	Underperform Votes 96 37.35%
Alvotech	Outperform Votes 6 46.15%	Underperform Votes 7 53.85%

Do insiders and institutionals have more ownership in GMAB or ALVO?

7.1% of Genmab A/S shares are owned by institutional investors. 1.5% of Genmab A/S shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Which has more risk & volatility, GMAB or ALVO?

Genmab A/S has a beta of 0.97, suggesting that its stock price is 3% less volatile than the S&P 500. Comparatively, Alvotech has a beta of -0.19, suggesting that its stock price is 119% less volatile than the S&P 500.

Does the media prefer GMAB or ALVO?

In the previous week, Genmab A/S had 4 more articles in the media than Alvotech. MarketBeat recorded 4 mentions for Genmab A/S and 0 mentions for Alvotech. Alvotech's average media sentiment score of 1.00 beat Genmab A/S's score of 0.87 indicating that Alvotech is being referred to more favorably in the news media.

Company	Overall Sentiment
Genmab A/S	Positive
Alvotech	Positive

Is GMAB or ALVO more profitable?

Genmab A/S has a net margin of 23.49% compared to Alvotech's net margin of -123.47%. Genmab A/S's return on equity of 14.64% beat Alvotech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Genmab A/S	23.49%	14.64%	12.37%
Alvotech	-123.47%	N/A	-35.87%

Do analysts recommend GMAB or ALVO?

Genmab A/S currently has a consensus price target of $45.20, suggesting a potential upside of 108.39%. Alvotech has a consensus price target of $18.00, suggesting a potential upside of 35.44%. Given Genmab A/S's higher probable upside, analysts plainly believe Genmab A/S is more favorable than Alvotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Genmab A/S	1 Sell rating(s)	3 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.50
Alvotech	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00

Summary

Genmab A/S beats Alvotech on 15 of the 18 factors compared between the two stocks.